Nabriva Therapeutics plc (NBRV) |
|
1.88 0.04 (2.17%)
|
02-03 15:59 |
|
Open: |
1.86 |
Pre. Close: |
1.84 |
|
High:
|
1.94 |
Low:
|
1.8101 |
|
Volume:
|
32,807 |
Market Cap:
|
6(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 3:49:26 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 2.77 One year: 3.24 |
| Support: |
Support1: 1.66 Support2: 1.21 |
| Resistance: |
Resistance1: 2.38 Resistance2: 2.77 |
| Pivot: |
1.59  |
| Moving Average: |
MA(5): 1.71 MA(20): 1.55 
MA(100): 2.2 MA(250): 5 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 91.4 %D(3): 91.7 |
| RSI: |
RSI(14): 57.5 |
| 52-week: |
High: 13.37 Low: 0.17 |
| Average Vol(K): |
3-Month: 96 (K) 10-Days: 32 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NBRV ] has closed above the upper band by 5.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.9 - 1.91 |
1.91 - 1.91 |
|
Low:
|
1.75 - 1.76 |
1.76 - 1.77 |
|
Close:
|
1.83 - 1.84 |
1.84 - 1.85 |
|
Company Description |
|
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. |
Headline News |
Tue, 31 Jan 2023
Do Traders Think Nabriva Therapeutics PLC - ADR (NBRV) Can Keep Climbing Tuesday? - InvestorsObserver
Tue, 10 Jan 2023
How Does Nabriva Therapeutics PLC - ADR (NBRV) Stock Rank on Wall Street Tuesday? - InvestorsObserver
Mon, 09 Jan 2023
Will Nabriva Therapeutics PLC - ADR (NBRV) Stay at the Top of the Healthcare Sector? - InvestorsObserver
Fri, 06 Jan 2023
Should You Hold Nabriva Therapeutics PLC - ADR (NBRV) in Biotechnology Industry? - InvestorsObserver
Fri, 06 Jan 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average ... - Investing.com
Fri, 06 Jan 2023
Sector Update : Healthcare Stocks Rise Friday, Mostly Trail Other Sectors - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
57 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
0.5 (%) |
|
% Held by Institutions
|
13.1 (%) |
|
Shares Short
|
109 (K) |
|
Shares Short P.Month
|
24 (K) |
Stock Financials |
|
EPS
|
-5.41 |
|
EPS Est Next Qtl
|
-0.5 |
|
EPS Est This Year
|
-2.29 |
|
EPS Est Next Year
|
-2 |
|
Book Value (p.s.)
|
1.57 |
|
Profit Margin (%)
|
-132 |
|
Operating Margin (%)
|
-129.3 |
|
Return on Assets (ttm)
|
-38 |
|
Return on Equity (ttm)
|
-89.9 |
|
Qtrly Rev. Growth
|
11.5 |
|
Gross Profit (p.s.)
|
0.05 |
|
Sales Per Share
|
0.62 |
|
EBITDA (p.s.)
|
-0.8 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-48 (M) |
|
Levered Free Cash Flow
|
-31 (M) |
Stock Valuations |
|
PE Ratio
|
-0.35 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.17 |
|
Price to Sales
|
2.97 |
|
Price to Cash Flow
|
-2.18 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-12-02 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
